First up this week are Patterson Belknap Webb & Tyler patent litigators Barbara Mullin, Aron Fischer and Andrew Cohen. You might remember that back in 2021 Mullin took home Litigator of the Week honors for fending off a generic drug maker’s patent challenge to Janssen’s Invega Sustenna, an antipsychotic drug with more than $1.5 billion in annual sales. In a decision made public this week, Mullin and a trial team co-led by Fischer and Cohen got a ruling from U.S. District Judge Evelyn Padin in New Jersey in a similar case preserving patent protection for Janssen’s Invega Trinza, a long-acting injectable antipsychotic drug used to treat schizophrenia which generates about $600 million in annual sales in the U.S. The judge’s ruling, which comes after a two-week bench trial last year and closing arguments this spring, bars the FDA from approving a proposed generic from Mylan until Janssen’s patent expires—a date currently set for April 5, 2036. The Patterson Belknap team also included Lachlan Campbell-Verduyn, Jay Cho, Joyce Nadipuram and Robert Quirk.
Katherine “Kat” Hacker of Bartlit Beck and co-counsel Christine Miller at Husch Blackwell extended Bayer’s defense win streak to seven trials in a row in cases where plaintiffs claim the herbicide Roundup caused their non-Hodgkin lymphoma. After a six-week trial and about five hours of deliberations, jurors in Clayton, Missouri this week sided with the company and turned back the plaintiff’s design defect, failure to warn and negligence claims. The Bartlit Beck team also included Mark Ouweleen, Lindley Brenza, Reid Bolton and Dawson Robinson.
